机构：[1]Department of Respiratory, Shanghai Chest Hospital, Shanghai, China[2]Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China[3]Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[4]General Medicine Department, Beijing Chest Hospital, Capital Medical University, Beijing, China[5]Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China[6]Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China[7]Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China四川省肿瘤医院[8]Department of Oncology, Fujian Cancer Hospital, Fuzhou, China[9]Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China
第一作者机构：[1]Department of Respiratory, Shanghai Chest Hospital, Shanghai, China
推荐引用方式(GB/T 7714)：
Zhong H.,Zhong R.,Qiao R.,et al.Phase I study of SHR-A2102, a nectin-4 targeted ADC, in patients with advanced solid tumors[J].ANNALS OF ONCOLOGY.2024,35:S513-S513.doi:10.1016/j.annonc.2024.08.715.
APA：
Zhong, H.,Zhong, R.,Qiao, R.,Lan, Q.,Yan, M....&Song, L..(2024).Phase I study of SHR-A2102, a nectin-4 targeted ADC, in patients with advanced solid tumors.ANNALS OF ONCOLOGY,35,
MLA：
Zhong, H.,et al."Phase I study of SHR-A2102, a nectin-4 targeted ADC, in patients with advanced solid tumors".ANNALS OF ONCOLOGY 35.(2024):S513-S513
医学